Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

akademie klasické homeopatie, spol. s r.o., ostrava array - 51982 graphites 98 c; 51984 graphites 229 c; 51900 graphites 999 c - tableta - c98-c229-c999 - homeopatika (ČeskÁ atc skupina)

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

boiron, messimy array - 50550 graphites - dilutio homeopathica - granule - 3ch-200ch - homeopatika (ČeskÁ atc skupina)

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

boiron, messimy array - 51127 agraphis nutans - dilutio homeopathica - granule - 2ch-200ch - homeopatika (ČeskÁ atc skupina)

Evropská unie - čeština - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresiva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriatická arthritiscosentyx, samostatně nebo v kombinaci s methotrexátem (mtx), je indikován pro léčbu aktivní psoriatické artritidy u dospělých pacientů, pokud odpověď na předchozí léčbu chorobu modifikující anti antirevmatickými léky (dmard) terapie byla nedostatečná. axiální spondylartritidy (axspa)ankylozující spondylitida (as, radiografické axiální spondylartritidy)cosentyx je indikován k léčbě aktivní ankylozující spondylitidy u dospělých, kteří nereagovali adekvátně na konvenční léčbu. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Evropská unie - čeština - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriáza - imunosupresiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Evropská unie - čeština - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - léky na léčbu nemocí kostí - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

atnahs pharma netherlands b.v., amsterdam array - 8392 kalcitriol - měkká tobolka - 0,25mcg - kalcitriol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

atnahs pharma netherlands b.v., amsterdam array - 8392 kalcitriol - měkká tobolka - 0,50mcg - kalcitriol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

theramex ireland limited, dublin array - 8468 alfakalcidol - měkká tobolka - 0,25mcg - alfakalcidol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

theramex ireland limited, dublin array - 8468 alfakalcidol - měkká tobolka - 1mcg - alfakalcidol